US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA), announced at the 5th China International Import Expo (CIIE). The collaboration will focus on exploring heart failure due to special causes, particularly thyroxine protein amyloid cardiomyopathy (ATTR-CM), aiming to revamp diagnosis and treatment protocols in China.
Partnership Objectives
The partnership aims to upgrade clinicians’ cognitive levels regarding ATTR-CM, assist in cause-based diagnosis and treatment of heart failure, and promote the construction of a China-specific model for diagnosis and treatment of heart failure. This initiative underscores Pfizer’s commitment to improving clinical outcomes for patients with complex cardiovascular conditions.
Long-Term Collaboration
Pfizer and the CCA have maintained a long-term collaborative relationship, focused on raising quality standards in clinical diagnosis and treatment of heart failure. Their efforts include establishing quality control standards, homogenizing diagnosis and treatment protocols, building capacity in cardiovascular specialty and multidisciplinary comprehensive diagnosis and treatment (MDT) teams, and improving the management level of clinicians for patients with heart failure.-Fineline Info & Tech
